Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)

Cancer Biology and Therapy

Volumn 7, Issue 6, 2008, Pages 974-982

  Chandran, Sachin S ^a   Banerjee, Sangeeta R ^b,c   Mease, Ron C ^b,c   Pomper, Martin G ^b,c   Denmeade, Samuel R ^a,b,c  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Docetaxel; Nanoparticle; Polyethlene glycol; Prostate cancer; PSMA; Targeted

Indexed keywords

2 [3 (5 AMINO 1 CARBOXYPENTYL) UREIDO]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 5 [7 (2,5 DIOXO PYRROLIDIN 1 YLOXYCARBONYL)HEPTANOYLAMINO]PENTYL]UREIDO]PENTANEDIOIC ACID; CARBOXYL GROUP; DOCETAXEL; MACROGOL; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UREA DERIVATIVE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MACROGOL DERIVATIVE; MEMBRANE ANTIGEN; POLYMER; TUMOR ANTIGEN; UREA;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; INTERSTITIUM; PROSTATE EPITHELIUM; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID TUMOR; CHEMISTRY; DRUG ANTAGONISM; ENDOCYTOSIS; EXTRACELLULAR MATRIX; MALE; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL LINE, TUMOR; ENDOCYTOSIS; EXTRACELLULAR MATRIX; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; POLYMERS; PROTEIN BINDING; UREA;

EID: 46749087806     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.6.5968     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Smigal C, Thun MJ. Cancer statistics, 2006. Ca-a Cancer Journal for Clinicians 2006; 56:106-30.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-24.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71:1098-109.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12.
6. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1995; 1:18-28.
7. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807-11.
8. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192-8.
9. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81-5.
10. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992; 21:63-73.
11. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326-34.
12. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996; 93:749-53.
13. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2:1445-51.
14. Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2004; 3:551-8.
15. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006; 66:9171-7.
16. Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther 2004; 3:597-603.
17. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103:6315-20.
18. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62:4029-33.
19. Nanus DM, Milowsky MI, Kostakoglu L, Smith Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170:84-8.
20. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11:4022-8.
21. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005; 4:1015-26.
22. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3:216-25.
23. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990; 50:6423-9.
24. Sant S, Poulin S, Hildgen P. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J Biomed Mater Res A 2008; [Epub ahead of print].
25. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55:217-50.
26. Lee JS, An TK, Chae GS, Jeong JK, Cho SH, Lee HB, Khang G. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm 2005; 59:169-75.
27. Li S, McCarthy S. Further investigations on the hydrolytic degradation of poly (DL-lactide). Biomaterials 1999; 20:35-44.
28. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28:5-24.
29. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B, Neale JH. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004; 47:1729-38.
30. Hu Y, Jiang XQ, Ding Y, Zhang LY, Yang CZ, Zhang JF, Chen JN, Yang YH. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)- poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. Biomaterials 2003; 24:2395-404.
31. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003; 54:249-57.
32. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003; 95:990-1000.
33. Chavanpatil MD, Khdair A, Panyam J. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol 2006; 6:2651-63.
34. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003; 14:4835-45.